Patrick Trown

Dr. Trown has been active in the Pharmaceutical/Biopharmaceutical industry for over 45 years. He held positions of increasing responsibility from researcher to Vice President at Lederle Laboratories, Hoffmann La Roche, Xoma Corporation, Onyx Pharmaceuticals and Jennerex Inc. He has extensive experience in the direction of research, preclinical development, the chemistry, manufacture and control of biopharmaceuticals, and interaction with FDA and international regulatory agencies.

Drugs for which he had a significant role in their development include alpha-interferon Roferon A®, a 5FU pro-drug Xeloda®, an immunosuppressive immunoconjugate CD5 Plus, an anti-sepsis monoclonal antibody E5®, a recombinant human protein for trauma/sepsis Neuprex®, a raf kinase inhibitor Nexavar®, selectively-replicating adenoviruses, e.g. ONYX-015, an enzyme replacement therapy for Mucopolysaccharidosis 1, Aldurazyme®, a vaccinia virus for the treatment of cancer JX-594 and a novel chimeric antibody-like molecule for the treatment of angiogenesis-related diseases hI-con1™.

Over the past 10 years, Dr. Trown has consulted for various biotechnology companies, including Iconic Therapeutics, BioMarin Pharmaceutical, Onyx Pharmaceuticals, Astex Technology Ltd., Gryphon Therapeutics, Ultragenyx and Cell Genesys on preclinical development of biopharmaceuticals and low molecular weight drugs.